Shares of Threshold Pharmaceuticals Inc. (THLD) were down 64% in extended trading on Thursday as the overall results from two phase II proof-of-concept clinical trials of its drug candidate Tarloxotinib didn't warrant further development of the compound.
from RTT - Biotech http://ift.tt/2dJ2cLR
via IFTTT
No comments:
Post a Comment